Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.71 |
| ▸ | CXCR4 | P61073 | 14/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | CCR2 | P41597 | 1/20 | 0.59 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21961925 | 1.00 | SIGMAR1 (0.71) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| Bromide SCHEMBL1259195 | 0.98 | SIGMAR1 (0.69) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL674945 | 0.91 | CXCR4 (0.75) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL674847 | 0.91 | CXCR4 (0.65) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL16855796 | 0.90 | CXCR4 (0.63) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL15855010 | 0.90 | SIGMAR1 (0.59) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL15858130 | 0.89 | SIGMAR1 (0.62) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL12320535 | 0.89 | SIGMAR1 (0.62) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL21799527 | 0.89 | PRMT6 (0.72) | SIGMAR1CXCR4MEN1CHRM2CHRM1 | |
| SCHEMBL6858101 | 0.89 | SIGMAR1 (0.62) | SIGMAR1CXCR4MEN1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291538-A1 | Macrocyclic Compositions And Metal Complexes For Bioimaging And Biomedical Applications | UNIV NAT YANG MING (TW) | 2015-10-15 | — | — | US | disclosed |
| US-20150291538-A1 | Macrocyclic Compositions And Metal Complexes For Bioimaging And Biomedical Applications | UNIV NAT YANG MING (TW) | 2015-10-15 | — | — | US | disclosed |
| US-9062009-B2 | Macrocyclic compounds and metal complexes for bioimaging and biomedical applications | NATIONAL YANG MING UNIVERSITY (TW) | 2015-06-23 | — | — | US | disclosed |
| US-9062009-B2 | Macrocyclic compounds and metal complexes for bioimaging and biomedical applications | NATIONAL YANG MING UNIVERSITY (TW) | 2015-06-23 | — | — | US | disclosed |
| US-20140187527-A1 | Macrocyclic Compounds And Metal Complexes For Bioimaging And Biomedical Applications | NATIONAL YANG MING UNIVERSITY (TW) | 2014-07-03 | — | — | US | disclosed |
| US-20140187527-A1 | Macrocyclic Compounds And Metal Complexes For Bioimaging And Biomedical Applications | NATIONAL YANG MING UNIVERSITY (TW) | 2014-07-03 | — | — | US | disclosed |
| US-RE42152-E1 | Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity | GENZYME CORPORATION (US) | 2011-02-15 | — | — | US | disclosed |
| EP-0619813-B1 | LINKED CYCLIC POLYAMINES WITH ACTIVITY AGAINST HIV | ANORMED INC (CA) | 2004-08-18 | — | — | EP | disclosed |
| EP-1223166-A1 | Linked cyclic polyamines with activity against hiv. | AnorMED Inc. (CA) | 2002-07-17 | — | — | EP | disclosed |
| US-5583131-A | FOR TREATMENT OR PREVENTION OF ACQUIRED IMMUNE DEFICIENCY SYNDROME, REDUCED TOXICITY | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1996-12-10 | — | — | US | disclosed |
| EP-0619813-A1 | LINKED CYCLIC POLYAMINES WITH ACTIVITY AGAINST HIV | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1994-10-19 | — | — | EP | disclosed |
| WO-1993012096-A1 | LINKED CYCLIC POLYAMINES WITH ACTIVITY AGAINST HIV | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187527-A1 | Macrocyclic Compounds And Metal Complexes For Bioimaging And Biomedical Applications | DNASE1L3, DNASE1, SNRPA | SIGMAR1 4596/4885CXCR4 3808/4885MEN1 576/4885 |
| US-20150291538-A1 | Macrocyclic Compositions And Metal Complexes For Bioimaging And Biomedical Applications | DNASE1, DNASE1L3, SNRPA | SIGMAR1 4531/4885CXCR4 4024/4885MEN1 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.